Source comparison
Tesamorelin vs Alternatives: Why Researchers Choose This GHRH Analog
Tesamorelin 2mg/day GHRH analog → pulsatile GH secretion 15–20% at 26 weeks Preserved or +1–2kg Neutral to slight improvement Gold standard for VAT-specific research. Physiological GH pattern minimises metabolic side effects while delivering targeted fat loss
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg/day
- GHRH analog → pulsatile GH secretion
- 15–20% at 26 weeks
- Preserved or +1–2kg
- Neutral to slight improvement
- Gold standard for VAT-specific research. Physiological GH pattern minimises metabolic side effects while delivering targeted fat loss
- Exogenous GH 2–4 IU/day
- Direct pharmacological GH
- 10–15% at 24 weeks
- Significant gain (+3–5kg)
- Often impaired. Elevated fasting glucose common
- Effective for lean mass gain but diabetogenic risk limits use in metabolic research; lacks VAT specificity of tesamorelin
- Sermorelin (GHRH analog)
- Minimal data. Likely 5–10%
- Modest preservation
- Likely neutral
- Shorter half-life than tesamorelin requires multiple daily doses; limited published VAT data in controlled trials
- CJC-1295 (modified GHRH)
- GHRH analog with extended half-life
- Limited clinical data
- Anecdotal reports only
- Unknown
- No Phase 3 data; used primarily in non-clinical settings; regulatory status unclear for research use
- GLP-1 agonists (semaglutide)
- Incretin mimetic → appetite suppression
- 5–8% total fat (not VAT-specific)
- Often lost during deficit
- Improved (primary mechanism)
- Excellent for overall weight loss but does not preferentially target visceral fat; lean mass loss occurs unless resistance training maintained
- The comparison reveals why tesamorelin help body composition research remains the preferred choice: it isolates visceral fat loss without the confounding variable of total caloric deficit (which GLP-1s require) or the metabolic liability of supraphysiological GH levels (which direct GH creates). When study design requires precision. Separating VAT effects from subcutaneous fat, lean mass, or appetite-driven weight loss. Tesamorelin is the tool that delivers clean data.
- Our peptide synthesis protocols at Real Peptides prioritise exact amino-acid sequencing and batch-level purity verification to ensure research-grade tesamorelin performs consistently across trials. Variability in peptide quality introduces noise into body composition data. A 2% difference in purity can mean a 10% difference in receptor binding affinity, which researchers can't afford when measuring outcomes as specific as L4–L5 visceral fat volume by CT.